SNCA as A Drug Target for Diabetes, Heart Failure and Cancer (G6622)

Target Name: SNCA

NCBI ID: G6622

SNCA

SNCA as A Drug Target for Diabetes, Heart Failure and Cancer

SNCA, or Sodium Chloride Content of Adequate Solution, is a drug target and a potential biomarker for several diseases, including diabetes, heart failure, and cancer. The discovery of SNCA as a drug target has the potential to revolutionize the treatment of these diseases.

SNCA is a protein that is expressed in various tissues and cells throughout the body. It is a key component of the extracellular matrix (ECM), which is a complex matrix of proteins, carbohydrates, and nucleic acids that surrounds and supports cells. SNCA plays a crucial role in the regulation of cell-cell adhesion, as well as the maintenance of tissue structure and function.

One of the key functions of SNCA is its role in the regulation of ion transport. Ions play a critical role in the function of many biological processes, including muscle contractions, nerve impulses, and signaling pathways. SNCA helps to regulate the movement of these ions across cell membranes, ensuring that cells receive the necessary nutrients and waste products while maintaining a stable internal environment.

In the context of diabetes, SNCA has been shown to play a potential role as a drug target. There are approximately 460 million diabetics worldwide, more than 90% of whom have type 2 diabetes. Diabetes is a hypermetabolic disease characterized by insulin resistance, which is characterized by persistent hyperglycemia. Insulin resistance is closely related to the obstruction of SNCA receptor binding on the cell membrane, which leads to a decrease in the cell's response to insulin. Therefore, SNCA becomes a promising target for the treatment of diabetes.

SNCA also has potential application value in the treatment of heart failure. Heart failure is a serious condition that can limit the function of the heart and become life-threatening. At present, the treatment of heart failure mainly includes drug treatment and surgical treatment. However, these treatments still have many limitations. Therefore, researchers are exploring new treatments, including SNCA. By using SNCA as a drug target, the ion balance on the cardiac cell membrane can be adjusted, thereby improving cardiac function and improving therapeutic effects.

SNCA has also been implicated in the treatment of cancer. Cancer cells are invasive and metastatic, making them difficult to eliminate with traditional treatments. However, studies have found that SNCA expression levels are altered in certain types of cancer. Therefore, SNCA can serve as a new cancer treatment target. Through drug intervention targeting SNCA, the growth and metastasis of cancer cells can be inhibited, thereby improving the therapeutic effect.

As a new drug target, SNCA has broad application prospects in drug development and treatment. However, to achieve this goal, a series of technical challenges and biological difficulties need to be overcome. First, drugs that specifically bind to SNCA need to be developed. Secondly, in-depth research on the role of SNCA in disease is needed to determine its effectiveness and safety as a drug target. In addition, rigorous clinical trials of drugs are needed to evaluate their therapeutic efficacy and safety.

In summary, SNCA, as a new drug target, has broad application prospects in the treatment of diseases such as diabetes, heart failure, and cancer. By developing drugs that specifically bind to SNCA and further studying the role of SNCA in the disease, we can provide people with better treatment options.

Protein Name: Synuclein Alpha

Functions: Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release (PubMed:28288128, PubMed:30404828, PubMed:20798282, PubMed:26442590). Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores (PubMed:28288128, PubMed:30404828). Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis (PubMed:30404828). Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5 (PubMed:20798282). This chaperone activity is important to sustain normal SNARE-complex assembly during aging (PubMed:20798282). Also plays a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity (PubMed:26442590)

The "SNCA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNCA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets